Advertisement
U.S. markets open in 27 minutes
  • S&P Futures

    5,306.75
    -1.50 (-0.03%)
     
  • Dow Futures

    40,171.00
    +27.00 (+0.07%)
     
  • Nasdaq Futures

    18,489.75
    -14.00 (-0.08%)
     
  • Russell 2000 Futures

    2,141.20
    +2.80 (+0.13%)
     
  • Crude Oil

    82.60
    +1.25 (+1.54%)
     
  • Gold

    2,230.80
    +18.10 (+0.82%)
     
  • Silver

    24.73
    -0.03 (-0.11%)
     
  • EUR/USD

    1.0814
    -0.0015 (-0.14%)
     
  • 10-Yr Bond

    4.2180
    +0.0220 (+0.52%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2645
    +0.0007 (+0.05%)
     
  • USD/JPY

    151.2380
    -0.0080 (-0.01%)
     
  • Bitcoin USD

    70,777.04
    +563.52 (+0.80%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.84
    +22.86 (+0.29%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Genentech: Omalizumab met its primary endpoint in Phase III trial, ASTERIA lll

Genentech, a member of the Roche Group announced results from a Phase III trial, ASTERIA II, which demonstrated that omalizumab met its primary endpoint in patients with moderate to severe chronic idiopathic urticaria, CIU, who remained symptomatic despite treatment with approved H1 antihistamine doses.

Advertisement